NO981578D0 - FremgangsmÕte for hemming av plasminogenaktivatorhemmer I - Google Patents

FremgangsmÕte for hemming av plasminogenaktivatorhemmer I

Info

Publication number
NO981578D0
NO981578D0 NO981578A NO981578A NO981578D0 NO 981578 D0 NO981578 D0 NO 981578D0 NO 981578 A NO981578 A NO 981578A NO 981578 A NO981578 A NO 981578A NO 981578 D0 NO981578 D0 NO 981578D0
Authority
NO
Norway
Prior art keywords
plasminogen activator
activator inhibitor
inhibiting plasminogen
inhibiting
inhibitor
Prior art date
Application number
NO981578A
Other languages
English (en)
Other versions
NO981578L (no
Inventor
David Thompson Berg
Brian William Grinnell
Mark Alan Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO981578D0 publication Critical patent/NO981578D0/no
Publication of NO981578L publication Critical patent/NO981578L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO981578A 1995-10-10 1998-04-07 FremgangsmÕte for hemming av plasminogenaktivatorhemmer I NO981578L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US501595P 1995-10-10 1995-10-10
PCT/US1996/016059 WO1997013511A1 (en) 1995-10-10 1996-10-07 Methods of inhibiting plasminogen activator inhibitor 1

Publications (2)

Publication Number Publication Date
NO981578D0 true NO981578D0 (no) 1998-04-07
NO981578L NO981578L (no) 1998-04-07

Family

ID=21713702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981578A NO981578L (no) 1995-10-10 1998-04-07 FremgangsmÕte for hemming av plasminogenaktivatorhemmer I

Country Status (20)

Country Link
US (1) US5731328A (no)
EP (1) EP0854715B1 (no)
JP (1) JPH11513665A (no)
KR (1) KR19990064099A (no)
CN (1) CN1199337A (no)
AR (1) AR003812A1 (no)
AT (1) ATE255414T1 (no)
AU (1) AU716655B2 (no)
CA (1) CA2234404A1 (no)
CO (1) CO4750819A1 (no)
CZ (1) CZ106098A3 (no)
DE (1) DE69630969T2 (no)
EA (1) EA001003B1 (no)
ES (1) ES2211981T3 (no)
HU (1) HUP9802348A3 (no)
NO (1) NO981578L (no)
NZ (1) NZ319948A (no)
PL (1) PL326294A1 (no)
WO (1) WO1997013511A1 (no)
ZA (1) ZA968444B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2006088011A1 (ja) * 2005-02-15 2006-08-24 Tokai University Educational System プラスミノーゲンアクチベーターインヒビター－１阻害剤
US8066991B2 (en) * 2005-10-11 2011-11-29 Amano Enzyme Usa Co., Ltd. Enzyme inhibitors of PAI-1
CN101544138B (zh) * 2008-03-26 2012-05-23 山东新北洋信息技术股份有限公司 热转印打印机碳带回收装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
DK0664121T3 (da) * 1993-12-21 2001-12-03 Lilly Co Eli Anvendelse af raloxifen og dets analoger til fremstilling af et medikament til behandling af aterosclerose og iskæmisk hjertesygdom

Also Published As

Publication number Publication date
AU7259696A (en) 1997-04-30
PL326294A1 (en) 1998-09-14
CN1199337A (zh) 1998-11-18
HUP9802348A3 (en) 1999-11-29
DE69630969T2 (de) 2004-10-21
EP0854715B1 (en) 2003-12-03
DE69630969D1 (de) 2004-01-15
KR19990064099A (ko) 1999-07-26
EA199800366A1 (ru) 1998-10-29
ES2211981T3 (es) 2004-07-16
ZA968444B (en) 1998-04-07
CO4750819A1 (es) 1999-03-31
AU716655B2 (en) 2000-03-02
AR003812A1 (es) 1998-09-09
NO981578L (no) 1998-04-07
US5731328A (en) 1998-03-24
CZ106098A3 (cs) 1999-03-17
HUP9802348A2 (hu) 1999-08-30
EP0854715A1 (en) 1998-07-29
CA2234404A1 (en) 1997-04-17
ATE255414T1 (de) 2003-12-15
EP0854715A4 (en) 2001-12-19
WO1997013511A1 (en) 1997-04-17
JPH11513665A (ja) 1999-11-24
EA001003B1 (ru) 2000-08-28
NZ319948A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
NO973635D0 (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO973009D0 (no) Fremgangsmåte for å inhibere kathepsin-k
NO960059L (no) Fremgangsmåte for behandling av en underjordisk formasjon
LV12102A (lv) Rotamazes funkciju inhibitori
EE9800187A (et) Trombiini inhibiitorite eelravimid
PL323710A1 (en) Reversible inhibitors of cysteinic protease
NO974554D0 (no) Fremgangsmåte for behandling av en underjordisk formasjon
NO975159L (no) Fremgangsmåte for kontroll av biologisk nedbrytning
NO960339D0 (no) Fremgangsmåte for å inhibere restenose
FI964137A (fi) Rotamaasi-entsyymiaktiivisuuden inhibiittoreita
ID19198A (id) Inhibitor metaloprotease heterosiklik
NO981708D0 (no) FremgangsmÕte for deteksjon av cyklooksygenase-2
IL122266A0 (en) Inhibitors of phospholipase A2
ID18416A (id) Inhibitor metaloprotease diheterosiklik
ZA969880B (en) Flame inhibitor composition and method of application
ATE230275T1 (de) Angiogense-inhibitor
FI971784A (fi) Apolipoproteiini B-synteesin estäjiä
PT927183E (pt) Inibidores espirociclicos de metaloproteases
NO965075D0 (no) Dispersjoner av flytpunktsreduserende midler
EE9700093A (et) Apolipoproteiin-B sünteesi inhiibitorid
NO981578D0 (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
AU5512096A (en) Method of inhibiting restenosis using calreticulin
NO944931D0 (no) Anvendelse av 2-fenyl-3-arroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580D0 (no) Fremgangsmåte for å inhibere melanom
NO965497L (no) Fremgangsmåte for kontrollert fiksering av avleiringsinhibitor i en underjordisk formasjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application